A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Author： Held Lauren A.   Rizzieri David   Long Gwynn D.   Gockerman Jon P.   Diehl Louis F.   Castro Carlos M. de   Moore Joseph O.   Horwitz Mitchell E.   Chao Nelson J.   Gasparetto Cristina  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.31, Iss.3, 2013-03, pp. : 172-176

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: A phase 2 trial

By Abou-Jawde Rony   Reed Janice   Kelly Megan   Walker Esteban   Andresen Steven   Baz Rachid   Karam Mary   Hussein Mohamad  

Medical Oncology, Vol. 23, Iss. 2, 2006-06 ,pp. : 263-272

Humana Press, Inc

Access to resources Recommend Favorite

Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: A clinical experience

By Subbarayan Pochi R.   Lima Mayra   Ardalan Bach  

Acta Oncologica, Vol. 46, Iss. 4, 2007-01 ,pp. : 557-561

Informa Healthcare

Access to resources Recommend Favorite

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignancies

By Ma Cynthia   Mandrekar Sumithra   Alberts Steven   Croghan Gary   Jatoi Aminah   Reid Joel   Hanson Lorelei   Bruzek Laura   Tan Angelina   Pitot Henry   Erlichman Charles   Wright John   Adjei Alex  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 2, 2007-02 ,pp. : 207-215

Springer Publishing Company

Access to resources Recommend Favorite

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

By Romano A.   Chiarenza A.   Consoli U.   Conticello C.   Forte S.   Uccello G.   Vetro C.   Cavalli M.   Coppolino F.   Palumbo G. A.   Di Raimondo F.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1038-1044

Oxford University Press

Access to resources Recommend Favorite

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

By Klisovic Rebecca B.   Blum William   Liu Zhongfa   Xie Zhiliang   Kefauver Cheryl   Huynh Lenguyen   Zwiebel James A.   Devine Steven M.   Byrd John C.   Grever Michael R.   Chan Kenneth K.   Marcucci Guido  

Leukemia and Lymphoma, Vol. 55, Iss. 6, 2014-06 ,pp. : 1332-1336

Informa Healthcare

Access to resources Recommend Favorite